Related Experiment Video

Updated: Nov 20, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K

Advances in anti-BRAF therapies for lung cancer

Giandomenico Roviello1, Alberto D'Angelo2, Marianna Sirico3,4

  • 1Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.

Investigational New Drugs
|January 21, 2021
PubMed

Insights

Targeting BRAF mutations in non-small cell lung cancer (NSCLC) shows promise. This review covers anti-BRAF therapies and clinical trial insights for BRAF-mutated NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
  • BRAF mutations are found in 0-3% of NSCLC cases, impacting cell growth pathways.
  • BRAF inhibitors have shown efficacy in other cancers like melanoma.

Purpose of the Study:

  • To review the current treatment landscape for BRAF-mutated NSCLC.
  • To analyze clinical trial data on anti-BRAF therapies in NSCLC.
  • To discuss future therapeutic strategies for this patient subgroup.

Main Methods:

  • Literature review of clinical trials and research studies.
  • Analysis of treatment outcomes for BRAF-mutated NSCLC patients.
  • Synthesis of current evidence on BRAF-targeted therapies.

Main Results:

  • Anti-BRAF therapies demonstrate efficacy in treating NSCLC with BRAF mutations.
  • Clinical trials provide valuable insights into treatment response and resistance mechanisms.
  • Emerging data suggests a growing role for targeted BRAF inhibition in NSCLC.

Conclusions:

  • BRAF-mutated NSCLC represents a distinct molecular subtype with therapeutic vulnerabilities.
  • Targeted BRAF inhibition is a viable treatment option, evolving with ongoing research.
  • Further clinical investigation is crucial to optimize anti-BRAF strategies in NSCLC.
Keywords:
BRAFLung cancerV600

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K